Development and validation of a local treatment for cervix cancer resulting from human papillomavirus infection

The main objective of the project is the development of an effective and safe local treatment, of the lesions of the cervix induced by HPV infection. This project results from the identification of a medical need and advisability of filling this need with two molecules managed by using the route of the most suitable administration. Within this framework, the specific objectives of the Colvir project are:

  • To obtain the clinical evidence (“proof of concept”) of the effectiveness and the harmlessness of a local treatment using chemo-attractants.
  • To obtain the minimal clinical evidence of the effectiveness and the harmlessness of a local treatment using Cidofovir (an antiviral synthetic molecule). In order to increase the effectiveness of both treatments a sequential application will be also investigated.
  • To develop the adequate formulations directly applied on the cervix

 

Consortium

Companies: Mithra (Coordinator), Arlenda

Universities: ULiège, Université Libre de Bruxelles

 

Contact:

Maud Jost: [email protected] – Femalon SPRL, a member of Uteron Pharma, a division of Actavis

Website: www.uteron.com / www.actavis.com